Case Overview

The Parties

The Patent at Issue

U.S. Patent No. US8142413B2 (Application No. US12/824734) covers a **coaxial guide catheter for interventional cardiology procedures**. Guide catheters are critical instruments used during percutaneous coronary interventions, providing support and access for delivery of therapeutic devices to coronary arteries. The coaxial design referenced in the patent relates to a nested catheter configuration optimized for enhanced support and trackability — commercially and clinically significant features in complex coronary anatomy cases.

Medtronic retained Wilmer Cutler Pickering Hale & Dorr LLP, a preeminent IP litigation firm, with a team including attorneys Brittany Blueitt Amadi, Hannah Elise Gelbort, Jeffrey Soller, Jennifer L. Graber, Madeleine C. Laupheimer, Mark Christopher Fleming, and Tasha Joy Bahal. Defendant law firm and agent data were not disclosed in available case records.

Litigation Timeline & Procedural History

The appeal was filed on April 8, 2022, with the Federal Circuit — the exclusive appellate court for U.S. patent cases — as the forum. The case remained active for 713 days, a duration consistent with complex patent appeals involving substantial technical and legal briefing, including potential oral argument.

The verdict cause is identified as Patentability / Invalidity-Cancellation Action, indicating that the central appellate dispute concerned whether the patent-in-suit should be upheld or canceled on validity grounds. This framing suggests the underlying proceeding likely involved a USPTO inter partes review (IPR) or similar administrative invalidity challenge, with the Federal Circuit reviewing the outcome on appeal. The basis of termination is recorded as Patent Upheld, confirming the appellate court’s affirmance of validity.

No chief judge data was specified in the available case record.

The Verdict & Legal Analysis

Outcome

The Court of Appeals for the Federal Circuit issued an AFFIRMED verdict in favor of Medtronic, Inc. and Medtronic Vascular, Inc., upholding U.S. Patent No. US8142413B2 as valid. The case closed on March 21, 2024. Specific damages figures were not applicable given the invalidity/cancellation posture of the appeal — the central question was patent survival, not monetary relief. No injunctive relief details were disclosed, consistent with the administrative validity focus of the proceeding.

Verdict Cause Analysis

The appellate dispute centered on patentability and invalidity, classically grounded in challenges such as anticipation under 35 U.S.C. § 102, obviousness under 35 U.S.C. § 103, or issues of written description and enablement under § 112. In interventional cardiology patent disputes, coaxial catheter innovations frequently face obviousness challenges based on combinations of prior art catheter references — a technically complex area where claim construction and prosecution history play decisive roles.

The Federal Circuit’s affirmance means the lower tribunal’s validity findings — whether from a PTAB panel or district court — withstood appellate scrutiny under the applicable standard of review. For obviousness determinations, the Federal Circuit reviews legal conclusions de novo while upholding factual findings (such as the scope of prior art and level of ordinary skill) unless clearly erroneous. The affirmance therefore validates not merely the outcome but the underlying factual and legal framework supporting patent validity.

Specific evidentiary details, expert testimony records, and written opinions were not available in the provided case data. Practitioners seeking full analytical depth should consult the Federal Circuit’s published opinion via Google Scholar or the USPTO PACER system.

Legal Significance

This ruling reinforces the durability of well-prosecuted medical device patents facing post-grant invalidity challenges. In an era where IPR petition filings remain a dominant defense strategy — with the PTAB instituting review in a substantial percentage of petitions — a Federal Circuit affirmance of validity signals meaningful precedential value for patent holders in the cardiovascular technology space.

For coaxial catheter technology specifically, the decision underscores that claim architecture carefully distinguished from prior art during prosecution can survive adversarial invalidity attacks at both the administrative and appellate levels. Patent practitioners should note the strategic value of robust prosecution records in establishing non-obviousness arguments that hold under Federal Circuit review.